Last reviewed · How we verify
NO-Immunosuppressive
At a glance
| Generic name | NO-Immunosuppressive |
|---|---|
| Sponsor | Spanish Network for Research in Infectious Diseases |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Fungal Infection Susceptibility
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (PHASE1, PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NA)
- Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
- Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus (PHASE2)
- Effect of Cognitive Therapy on Immunosuppressive Treatment Compliance and Motivation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |